Genetic Testing in Clinical Settings

被引:40
作者
Franceschini, Nora [1 ]
Frick, Amber [2 ]
Kopp, Jeffrey B. [3 ]
机构
[1] Univ N Carolina, Gillings Sch Publ Hlth, Dept Epidemiol, Chapel Hill, NC 27516 USA
[2] Univ N Carolina, UNC Eshelman Sch Pharm, Div Pharmacotherapy & Expt Therapeut, Chapel Hill, NC 27516 USA
[3] NIDDK, Kidney Dis Branch, NIH, Bethesda, MD 20892 USA
关键词
IMPLEMENTATION CONSORTIUM GUIDELINES; DOMINANT POLYCYSTIC KIDNEY; STEVENS-JOHNSON-SYNDROME; HLA-B GENOTYPE; HYPERSENSITIVITY SYNDROME; COST-EFFECTIVENESS; GENOMIC MEDICINE; AMERICAN-COLLEGE; INDUCED MYOPATHY; CPIC GUIDELINES;
D O I
10.1053/j.ajkd.2018.02.351
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Genetic testing is used for screening, diagnosis, and prognosis of diseases consistent with a genetic cause and to guide drug therapy to improve drug efficacy and avoid adverse effects (pharmacogenomics). This In Practice review aims to inform about DNA-related genetic test availability, interpretation, and recommended clinical actions based on results using evidence from clinical guidelines, when available. We discuss challenges that limit the widespread use of genetic information in the clinical care setting, including a small number of actionable genetic variants with strong evidence of clinical validity and utility, and the need for improving the health literacy of health care providers and the public, including for direct-to-consumer tests. Ethical, legal, and social issues and incidental findings also need to be addressed. Because our understanding of genetic factors associated with disease and drug response is rapidly increasing and new genetic tests are being developed that could be adopted by clinicians in the short term, we also provide extensive resources for information and education on genetic testing.
引用
收藏
页码:569 / 581
页数:13
相关论文
共 80 条
[1]   ALLOPURINOL HYPERSENSITIVITY SYNDROME - A REVIEW [J].
ARELLANO, F ;
SACRISTAN, JA .
ANNALS OF PHARMACOTHERAPY, 1993, 27 (03) :337-343
[2]   Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing [J].
Birdwell, K. A. ;
Decker, B. ;
Barbarino, J. M. ;
Peterson, J. F. ;
Stein, C. M. ;
Sadee, W. ;
Wang, D. ;
Vinks, A. A. ;
He, Y. ;
Swen, J. J. ;
Leeder, J. S. ;
van Schaik, R. H. N. ;
Thummel, K. E. ;
Klein, T. E. ;
Caudle, K. E. ;
MacPhee, I. A. M. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 98 (01) :19-24
[3]   Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing [J].
Caudle, K. E. ;
Rettie, A. E. ;
Whirl-Carrillo, M. ;
Smith, L. H. ;
Mintzer, S. ;
Lee, M. T. M. ;
Klein, T. E. ;
Callaghan, J. T. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 96 (05) :542-548
[4]   Incorporation of Pharmacogenomics into Routine Clinical Practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline Development Process [J].
Caudle, Kelly E. ;
Klein, Teri E. ;
Hoffman, James M. ;
Mueller, Daniel J. ;
Whirl-Carrillo, Michelle ;
Gong, Li ;
McDonagh, Ellen M. ;
Sangkuhl, Katrin ;
Thorn, Caroline F. ;
Schwab, Matthias ;
Agundez, Jose A. G. ;
Freimuth, Robert R. ;
Huser, Vojtech ;
Lee, Ming Ta Michael ;
Iwuchukwu, Otito F. ;
Crews, Kristine R. ;
Scott, Stuart A. ;
Wadelius, Mia ;
Swen, Jesse J. ;
Tyndale, Rachel F. ;
Stein, C. Michael ;
Roden, Dan ;
Relling, Mary V. ;
Williams, Marc S. ;
Johnson, Samuel G. .
CURRENT DRUG METABOLISM, 2014, 15 (02) :209-217
[5]   Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference [J].
Chapman, Arlene B. ;
Devuyst, Olivier ;
Eckardt, Kai-Uwe ;
Gansevoort, Ron T. ;
Harris, Tess ;
Horie, Shigeo ;
Kasiske, Bertram L. ;
Odland, Dwight ;
Pei, York ;
Perrone, Ronald D. ;
Pirson, Yves ;
Schrier, Robert W. ;
Torra, Roser ;
Torres, Vicente E. ;
Watnick, Terry ;
Wheeler, David C. .
KIDNEY INTERNATIONAL, 2015, 88 (01) :17-27
[6]   Autosomal Dominant Polycystic Kidney Disease: Core Curriculum 2016 [J].
Chebib, Fouad T. ;
Torres, Vicente E. .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2016, 67 (05) :792-810
[7]   HLA-B alleles associated with severe cutaneous reactions to antiepileptic drugs in Han Chinese [J].
Cheung, Ying-Kit ;
Cheng, Suk-Hang ;
Chan, Ernest J. M. ;
Lo, Su V. ;
Ng, Margaret H. L. ;
Kwan, Patrick .
EPILEPSIA, 2013, 54 (07) :1307-1314
[8]   Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Ivacaftor Therapy in the Context of CFTR Genotype [J].
Clancy, J. P. ;
Johnson, S. G. ;
Yee, S. W. ;
McDonagh, E. M. ;
Caudle, K. E. ;
Klein, T. E. ;
Cannavo, M. ;
Giacomini, K. M. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 (06) :592-597
[9]  
Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3
[10]   Genetic Complexity of Autosomal Dominant Polycystic Kidney and Liver Diseases [J].
Cornec-Le Gall, Emilie ;
Torres, Vicente E. ;
Harris, Peter C. .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2018, 29 (01) :13-23